Dyax's HAE drug Kalbitor delayed in US by REMS
This article was originally published in Scrip
Executive Summary
The US FDA is requesting a formal risk evaluation and mitigation strategy (REMS), but no additional clinical trials, before it will approve Dyax's Kalbitor (ecallantide; DX88) for treating acute attacks of hereditary angioedema (HAE).